ARS Pharmaceuticals, Inc. (SPRY): Operating Income

Annual figures by period end, from SEC filings.

-$179.45M

Year ended 2025-12-31

-$216.27M

Trailing 12 months to 2026-06-30

2020-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$179.45M	n/m	2026-03-09, From 2025-01-01
2024-12-31	-$3.08M	n/m	2026-03-09, From 2024-01-01
2023-12-31	-$67.52M	n/m	2025-03-20, From 2023-01-01
2022-12-31	-$35.52M	n/m	2024-03-21, From 2022-01-01
2021-12-31	-$19.45M	n/m	2023-03-23, From 2021-01-01
2020-12-31	-$32.92M	n/a	2022-03-31, From 2020-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
ARS Pharmaceuticals, Inc. (SPRY)	2025-12-31	-$179.45M	n/m
Nurix Therapeutics, Inc. (NRIX)	2025-11-30	-$285.67M	n/m
Standard Biotools Inc. (LAB)	2025-12-31	-$110.25M	n/m
Arcturus Therapeutics Holdings Inc. (ARCT)	2025-12-31	-$76.26M	n/m
ADC Therapeutics SA (ADCT)	2025-12-31	-$121.50M	n/m
Cytokinetics Inc (CYTK)	2025-12-31	-$612.26M	n/m
Eton Pharmaceuticals, Inc. (ETON)	2025-12-31	-$844.0K	n/m
CytomX Therapeutics, Inc. (CTMX)	2025-12-31	-$22.36M	n/m
AbCellera Biologics Inc. (ABCL)	2025-12-31	-$217.10M	n/m

Compare SPRY, NRIX, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗